(Total Views: 227)
Posted On: 03/22/2019 1:09:38 PM
Post# of 154090
I just looked at the clinical trial site and agree that the "3+3" discussion does not seems to match what is noted on the clinical trial site.
It states each cohort (A at 350 mg, B at 525 mg and C at 700 mg) is the respective dosage of PRO 140 weekly and AUC 5 Carboplatin every 3 weeks.
The Primary Outcome Measures for Phase 1b: "Maximum Tolerated Dose (MTD) of leronlimab (PRO 140) when combined with carboplatin AUC5 [ Time Frame: Cycle 1 (21 days) ]."
I understand this to mean the entire phase will only be 1 cycle and last 21 days. I guess it could possibly be interpreted as each cycle is 21 days with multiple cycles....but that doesn't align with how they describe the Phase II "Time Frame: Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment."
It states each cohort (A at 350 mg, B at 525 mg and C at 700 mg) is the respective dosage of PRO 140 weekly and AUC 5 Carboplatin every 3 weeks.
The Primary Outcome Measures for Phase 1b: "Maximum Tolerated Dose (MTD) of leronlimab (PRO 140) when combined with carboplatin AUC5 [ Time Frame: Cycle 1 (21 days) ]."
I understand this to mean the entire phase will only be 1 cycle and last 21 days. I guess it could possibly be interpreted as each cycle is 21 days with multiple cycles....but that doesn't align with how they describe the Phase II "Time Frame: Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment."
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
